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COMMENTARY
Current insights into the relationship 
between the gut microbiome and Sjögren’s 
syndrome
Taco A. van der Meulen1* , Frans G. M. Kroese2, Hendrika Bootsma2, Fred K. L. Spijkervet1 and Arjan Vissink1
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Dear editor,
With interest we read the recent publication by Mendez 
et  al. [1] entitled ‘Gut microbial dysbiosis in individuals 
with Sjögren’s syndrome’ in which the authors report 
that individuals with dry eye signs have gut microbiome 
alterations compared to healthy controls. They conclude 
that their study sets the foundation for gut microbiome 
modulation as a potential therapeutic target for patients 
with dry eye measures.
The aim of the study by Mendez et al. [1] was to evalu-
ate the gut microbiome in patients with dry eye, with or 
without SS and to correlate microbiome profiles to clini-
cal parameters, in general only related with dry eye. In 
their cohort of 21 healthy controls and 21 patients with 
dry eye signs, only 13 patients with dry eyes (62%) ful-
filled the 2016 American College of Rheumatology cri-
teria for SS [2]. Although Mendez et  al. shortly discuss 
the heterogeneity of their patient population as a limita-
tion of their study, it is unclear whether the group of SS 
patients was composed of only primary SS (pSS) patients 
or of a combination of primary and secondary SS (sSS) 
patients. Four out of 13 (31%) SS patients in their study 
were male patients, whereas in pSS the female:male ratio 
is 10:1 [3]. Furthermore, 23% of their SS patients (3 out 
of 13) had a comorbid autoimmune disease, which may 
indicate that these patients had sSS. Unfortunately, 
Mendez et  al. [1] do not mention which autoimmune 
comorbid diseases these three SS patients suffered from. 
The possible mixture of pSS and sSS patients in their SS-
group may have influenced the findings in the gut micro-
biome of their SS patients. The comorbid autoimmune 
diseases mentioned in the study of Mendez et al. [1] (i.e., 
rheumatoid arthritis, systemic lupus erythematosus, pso-
riatric arthritis and systemic sclerosis) are on their own 
also related to changes in the gut microbiome [4]. Thus, 
their SS patient group is heterogeneous and not repre-
sentative for the average pSS or sSS population in the 
United States or Europe [5]. In addition to this heteroge-
neity, comparison with healthy controls is hampered by 
the notion that controls were all male and were younger 
than the patient groups. Sex and age both affect the com-
position of the intestinal microbiota [6].
The main difference Mendez et  al. [1] observed in 
the gut microbial composition of SS dry eye (SDE) 
patients and non-SS dry eye (NDE) patients compared 
with healthy controls was a significant difference in 
the Unweighted-Unifrac Principal coordinate analysis 
(PCoA). However, the gut microbial composition of SDE 
and NDE patients did not differ significantly, suggest-
ing that the dysbiosis in gut microbial composition in SS 
patients is not disease specific, but, e.g., related to dry eye 
signs. It would be of interest to apply essential compara-
tive statistics to support and substantiate the dysbiosis 
seen by PCoA.
Several studies analyzed the gut microbiome in pSS 
patients [6–10], but for some reason Mendez et al. lim-
ited the comparison of their data only to the study by 
de Paiva et  al. [7]. Mendez et  al. stated that a similar 
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and Bacteroides was found in both studies [1, 7]. How-
ever, de Paiva et al. [7] performed a pilot study compar-
ing the gut microbiome from 10 pSS patients with data 
from 45 samples of healthy individuals who participated 
in the Human Microbiome Project. Direct comparison 
of microbiome samples between two different cohorts is 
highly at risk for false positive findings, because of meth-
odological differences between cohorts, ranging from 
fecal sampling to DNA analysis.
Two other studies on gut microbiome in pSS reported a 
statistically significant higher relative abundance of phy-
lum Bacteroidetes in the gut microbiome of pSS patients 
compared to controls [6, 9]. The observed tendency of 
a lower relative abundance of genus Bacteroides in pSS 
patients compared to controls in the studies by Mendez 
et al. [1] and de Paiva et al. [7] was not statistically sig-
nificant, and markedly contrasted our own study showing 
significantly higher relative abundance of genus Bacte-
roides in pSS patients (n = 39) than in population con-
trols (n = 965) [6]. Furthermore, we were able to identify 
three Bacteroides species (i.e., B. vulgatus, B. uniformis 
and B. ovatus) of which the relative abundance was signif-
icantly higher in pSS patients than in population controls 
[6]. Another Bacteroides species, Bacteroides thetaio-
taomicron (B. theta), showed a tendency to be higher 
in pSS patients than in controls [6]. B. theta has been 
suggested as a potential gut pathobiont (i.e., a potential 
pathogenic micro-organism, which, under normal cir-
cumstances, is harmless) in patients with anti-Ro60 auto-
antibodies [11]. Lysates of B. theta bind to serum from 
anti-Ro60-positive patients with systemic lupus ery-
thematosus. Furthermore, B and T cell responses to the 
Ro60-protein occurred after monocolonization of mice 
with B. theta, subsequently leading to enhanced lupus-
like disease in mice [11]. Because anti-Ro60 autoantibod-
ies are observed in up to 70% of pSS patients, the findings 
of Greiling et al. [11] may suggest a potential role for B. 
theta in the pathogenesis for pSS also. However, there is 
no evidence for an association between the presence of 
anti-Ro60 auto-antibodies in serum and B. theta relative 
abundance in fecal samples of pSS patients or patients 
with systemic lupus erythematosus [6, 11]. Thus, there is 
currently more evidence supporting that a higher rather 
than a lower relative abundance of Bacteroides species is 
related to having pSS [1, 6, 9, 11].
Taken together, we conclude that we are far beyond 
drawing more definite conclusions about possible roles 
of particular bacterial species or groups of bacteria in the 
pathogenesis of SS (and dry eye disease). Future studies 
assessing the role of the human microbiome in pSS patients, 
should significantly increase in number of well-defined 
pSS patients [6]. Bacterial compositions on the ocular sur-
face and in the oral cavity have been associated with pSS. 
Therefore, future studies should include not only gut, but 
also oral and ocular microbiome samples to obtain a com-
plete picture of the microbiome – pSS connection [12].
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